209 related articles for article (PubMed ID: 31619751)
1. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.
Ma H; Zhao C; Zhao Z; Hu L; Ye F; Wang H; Fang Z; Wu Y; Chen X
Cancer Gene Ther; 2020 Sep; 27(9):702-714. PubMed ID: 31619751
[TBL] [Abstract][Full Text] [Related]
2. Specific Glioma Prognostic Subtype Distinctions Based on DNA Methylation Patterns.
Chen X; Zhao C; Zhao Z; Wang H; Fang Z
Front Genet; 2019; 10():786. PubMed ID: 31572431
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
[TBL] [Abstract][Full Text] [Related]
4. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
5. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival.
Ma X; Shang F; Zhu W; Lin Q
Expert Rev Neurother; 2017 Sep; 17(9):941-946. PubMed ID: 28685624
[TBL] [Abstract][Full Text] [Related]
8. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
9. A long non-coding RNA signature in glioblastoma multiforme predicts survival.
Zhang XQ; Sun S; Lam KF; Kiang KM; Pu JK; Ho AS; Lui WM; Fung CF; Wong TS; Leung GK
Neurobiol Dis; 2013 Oct; 58():123-31. PubMed ID: 23726844
[TBL] [Abstract][Full Text] [Related]
10. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
[TBL] [Abstract][Full Text] [Related]
11. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.
Zhang S; Wang Y; Gu Y; Zhu J; Ci C; Guo Z; Chen C; Wei Y; Lv W; Liu H; Zhang D; Zhang Y
Mol Oncol; 2018 Jun; 12(7):1047-1060. PubMed ID: 29675884
[TBL] [Abstract][Full Text] [Related]
12. Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.
Bernal Rubio YL; González-Reymúndez A; Wu KH; Griguer CE; Steibel JP; de Los Campos G; Doseff A; Gallo K; Vazquez AI
G3 (Bethesda); 2018 Nov; 8(11):3627-3636. PubMed ID: 30228192
[TBL] [Abstract][Full Text] [Related]
13. Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma.
Zhou J; Guo H; Liu L; Hao S; Guo Z; Zhang F; Gao Y; Wang Z; Zhang W
J Cell Mol Med; 2021 Feb; 25(3):1633-1644. PubMed ID: 33449451
[TBL] [Abstract][Full Text] [Related]
14. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
17. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
20. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]